Deals
China Cord Blood Soars as Rival Buyout Bid Valued 72% Higher
This article is for subscribers only.
China Cord Blood Corp. surged the most in a year as the stem-cell storage provider received a competing buyout bid that exceeded the one its biggest shareholder made in April by 72 percent.
The stock rallied 14 percent to $6.69 in New York on Thursday. Trading volume of 2.1 million shares was more than 7 times the daily average of the past three months. It was the best performance in the Bloomberg China-US Equity Index, which was unchanged at 122.31.